Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.  Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... Colo. , Dec. 19, 2014  Monarch America ... Cannabis Kinetics Corp.) is pleased to provide this review ... continued growth in 2015. "Over this past ... goals and I am extremely proud to say that ... position today than it has ever been," stated ...
(Date:12/19/2014)... -- Somewhere between dropping five pounds and cooking more ... Audicus , a next-generation hearing aids company, will help ... Hearing loss is the third most common chronic ... often unaddressed. Forty-eight million Americans have hearing loss, but ... due to price. Hearing aids traditionally cost $7,000 per ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... 2010 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... to offer its common stock in a registered public offering ... Act of 1933. Stereotaxis also intends to grant the underwriters ... common stock to cover over-allotments, if any. Stereotaxis ...
... 10, 2010 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, ...   Interested parties may access a live webcast ... It is recommended that listeners log on 15 ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:12/20/2014)... 2014 BambooIndustry.com is a ... business has announced its bamboo flooring promotion for ... material from certified suppliers, and offers the best ... In the current promotion, all customers can enjoy ... they say they know BambooIndustry.com from press releases. ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
(Date:12/20/2014)... The print component of Healthy Aging is distributed ... 160,000 copies and an estimated readership of 420,000. The ... media strategy and across a network of top news ... of the campaign, click here . , The ... of CTV’s The Social. Lainey Lui, Melissa Grelo, ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New ... a decade. They’ve treated over 40,000 patients while carrying ... alternative to the Paramus area. , For 2015, ... their staff of top-notch board certified physicians: Christine Milosis MD, ... These new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... CA (PRWEB) December 20, 2014 Atore, ... Innovation company just launched first birthday focused portal on ... “MERRY BIRTHDAY MESSAGE” launched in both US and Japan. ... BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY ... everyone’s birthday around the world. , Features, Choose from ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... the first in the country to offer skin transplant ... with the skin disease vitiligo. The surgery, known ... taken from normally pigmented areas of the body and ... restore pigmentation. It is performed under local anesthesia as ...
... one day serve as an alternative to steroid medications and ... on research findings at the Salk Institute for Biological Studies. ... in Salk,s Laboratory of Genetics and Ronald M. Evans, the ... that defends the body against cancer also plays a key ...
... Cypress, CA -- As many as 10 million American ... gastrointestinal and urinary tract difficulties and infertility due to ... the lining of the uterus the endometrium ... uterus. This year,s annual meeting of gynecologic laparoscopic ...
... sun can give rise to skin cancer has increased, so ... can give rise to contact allergy when exposed to the ... skin allergy. Scientists at the University of Gothenburg and Chalmers ... UV filter that does not have undesired effects., , "Unfortunately, ...
... TUESDAY, Oct. 25 (HealthDay News) -- Researchers have identified ... effect on the rate at which men experience an ... 144 experienced U.S. male pilots over the age of ... test three times over two years. The participants included ...
... 25, 2011 Researchers at Tenon Hospital, Paris, France, ... improved after cataract surgery also showed improvement in cognitive ... Brigitte Girard, MD, will discuss her team,s results today ... This is the first study to specifically assess ...
Cached Medicine News:Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 2Health News:Henry Ford Hospital first in United States to offer MKTP surgery as treatment option for vitiligo 3Health News:New anti-inflammatory drugs might help avoid side effects of steroids 2Health News:New anti-inflammatory drugs might help avoid side effects of steroids 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 2Health News:Close-up on endometriosis at 40th AAGL Global Congress 3Health News:Close-up on endometriosis at 40th AAGL Global Congress 4Health News:A substance from bacteria can lead to allergy-free sunscreen 2Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Mood, cognition and sleep patterns improve in Alzheimer's patients after cataract surgery 2
... 30 years, Digisonics has set the ... the first review station, the only ... the best multi-modality reporting., ,DigiView cardiology ... review workstations, professional reporting choices, an ...
... Rapid measurement of colloid osmotic (oncotic) ... onset in clinical situations. Uses a ... chambers to simulate the role of ... establishment of osmotic pressure responsible for ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
Medicine Products: